Table 2.
Characteristics | High-MPV/PC Ratio (28/191; 14.7%) | Low-MPV/PC Ratio (163/191; 85.3%) | p-Value |
---|---|---|---|
Age (years) | |||
≤65 | 12 (42.9%) | 103 (63.2%) | |
>65 | 16 (57.1%) | 60 (36.8%) | 0.06 |
Sex | |||
Female | 6 (21.4%) | 66 (40.5%) | |
Male | 22 (78.6%) | 97 (59.5%) | 0.06 |
Body mass index (mean ± SD) | 25.96 ± 3.7 | 28.15 ± 16.00 | 0.49 |
Preoperative KPS | |||
≥70 | 27 (96.4%) | 158 (96.9%) | |
<70 | 1 (3.6%) | 5 (3.6%) | 0.99 |
Secondary malignant neoplasm | |||
Present | 2 (7.1%) | 14 (8.6%) | |
Absent | 26 (92.9%) | 149 (91.4%) | 0.99 |
Dexamethasone intake | |||
≥7 days | 10 (35.7%) | 86 (53.1%) | |
<7 days | 18 (64.3%) | 76 (46.9%) | 0.31 |
Tumor area (mean ± SD), mm2 | 1353.99 ± 1113.8 | 1399.16 ± 947.1 | 0.84 |
Peritumoral edema (mean ± SD), mm | 24.8 ± 13.4 | 22.9 ± 10.4 | 0.33 |
Sawaya | |||
1 | 3 (10.7%) | 23 (14.1%) | |
≥2 | 25 (89.3%) | 140 (85.9%) | 0.77 |
Extent of resection | |||
GTR | 19 (67.8%) | 127 (77.9%) | |
STR | 9 (32.1%) | 36 (22.1%) | 0.24 |
IDH-1 mutation (available in 181 patients) | 1/26 (3.8%) | 15/155 (9.7%) | 0.48 |
MGMT promoter hypermethylation (available in 187 patients) | 13/28 (46.4%) | 84/159 (52.8%) | 0.55 |
MIB-I labeling index (mean ± SD), | 18.33 ± 7.76 | 15.96 ± 7.38 | 0.15 |
MPV, Mean Platelet Volume; PC, Platelet Count; SD, Standard deviation; KPS, Karnofsky Performance Status; GTR, Gross total resection; STR, Subtotal resection; IDH-1, Isocitrate dehydrogenase-1; MGMT, O-6-methylguanine-DNA methyltransferase; MIB-1, Molecular Immunology Borstel-1.